Abstract: Systems and methods for neuronavigation in accordance with embodiments of the invention are illustrated. Targeting systems and methods as described herein can generate personalized stimulation targets for the treatment of mental conditions. In many embodiments, direct stimulation of a personalized the stimulation target indirectly impacts a brain structure that is more difficult to reach via the stimulation modality. In various embodiments, the mental condition is major depressive disorder. In a number of embodiments, the mental condition is suicidal ideation.

Abstract: Systems and methods for treatment verification and re-treatment with iboga alkaloids in accordance with embodiments of the invention are illustrated. One embodiment includes obtaining a first arterial spin labeling (ASL) scan of a patient's brain pre-treatment with an iboga-alkaloid for a neuropsychiatric condition, obtaining a second ASL scan of the patient's brain post-treatment, measuring changes in regional cerebral blood flow (rCBF) in a left orbitofrontal cortex, left insula, right cingulate cortex, and left putamen of the patient's brain based on the first ASL scan and the second ASL scan, determining that the treatment succeeded when either (i) rCBF increased by at least 0.1 in the left orbitofrontal cortex, or (ii) rCBF increased by any amount in the left orbitofrontal cortex and in at least two of the left insula, right cingulate cortex, and left putamen, and determining that the treatment failed when it is not determined that the treatment succeeded.

Abstract: Methods for treating a neuropsychiatric disorder by administering an iboga alkaloid and a cardioprotective agent in conjunction with analysis of brain image data is described. Also described are methods to improve brain health and to slow or reverse brain aging by disorder by administering an iboga alkaloid and a cardioprotective agent, where analysis of brain image data is used to monitor and/or evaluate treatment effectiveness.

Abstract: Compositions comprising an iboga alkaloid and a cardioprotective agent are provided. Use of the compositions in treating neuropsychiatric disorders are described, where the cardioprotective agent is administered before, during and/or after the iboga alkaloid.

Abstract: Systems and methods for predicting and treating relapses for neurological conditions in accordance with embodiments of the invention are illustrated. One embodiment includes a method for predicting and treating a clinical neurological condition relapse. The method includes steps for selecting a threshold heart rate variability value for a patient suffering from a clinical neurological condition, monitoring, using a cardiac monitor, the heart rate variability of the patient over time, providing an indicator that a relapse is imminent when the heart rate variability of the patient falls below the threshold heart rate variability value, and treating the patient using a transcranial magnetic stimulation device by applying an accelerated theta burst stimulation protocol where the transcranial magnetic stimulation target is the left prefrontal dorsolateral cortex.

Abstract: Systems and methods for treatment of neurological conditions using aTBS in accordance with embodiments of the invention are illustrated. One embodiment includes a method for treating neurological conditions, including generating a personalized accelerated theta burst stimulation (aTBS) target representing a location in a patient's brain related to a neurological condition, placing a TMS device relative to the patient's brain such that the focus of the magnetic field is over the aTBS target, applying TMS to the aTBS target according to an aTBS protocol to the brain using the TMS device to alleviate the neurological condition.

Abstract: Methods for treating a neuropsychiatric disorder by administering an iboga alkaloid and a cardioprotective agent in conjunction with analysis of brain image data is described. Also described are methods to improve brain health and to slow or reverse brain aging by disorder by administering an iboga alkaloid and a cardioprotective agent, where analysis of brain image data is used to monitor and/or evaluate treatment effectiveness.

Abstract: Compositions comprising an iboga alkaloid and a cardioprotective agent are provided. Use of the compositions in treating neuropsychiatric disorders are described, where the cardioprotective agent is administered before, during and/or after the iboga alkaloid.

Abstract: Systems and methods for neuronavigation in accordance with embodiments of the invention are illustrated. Targeting systems and methods as described herein can generate personalized stimulation targets for the treatment of mental conditions. In many embodiments, direct stimulation of a personalized the stimulation target indirectly impacts a brain structure that is more difficult to reach via the stimulation modality. In various embodiments, the mental condition is major depressive disorder. In a number of embodiments, the mental condition is suicidal ideation.

Abstract: Systems and methods for neuronavigation in accordance with embodiments of the invention are illustrated. Targeting systems and methods as described herein can generate personalized stimulation targets for the treatment of mental conditions. In many embodiments, direct stimulation of a personalized the stimulation target indirectly impacts a brain structure that is more difficult to reach via the stimulation modality. In various embodiments, the mental condition is major depressive disorder. In a number of embodiments, the mental condition is suicidal ideation.

Abstract: Systems and methods for increasing hypnotizability in accordance with embodiments of the invention are illustrated. One embodiment includes a method of treating a recipient using hypnotherapy, including applying neurostimulation to a recipient's brain such that functional connectivity between an anterior cingulate cortex (ACC) and a dorsolateral prefrontal cortex (DLPFC) of the recipient's brain is increased, and activity in the ACC is decreased, and applying hypnotherapy in order to treat a condition of the recipient. In a further embodiment, the condition is selected from the group consisting of depression, anxiety, phobia, pain, stress, disordered eating, sleep disorders, posttraumatic stress, and addiction.

Abstract: Systems and methods for entropy-based treatment in accordance with embodiments of the invention are illustrated. One embodiment includes a method for treating a neurological condition, including obtaining a functional magnetic resonance imaging (fMRI) scan of a patient's brain, identifying a plurality of regions of interest (ROIs) in the fMRI scan, calculating entropy metrics for each ROI in the plurality of ROIs, selecting a treatment from a plurality of treatments for the neurological condition based on the entropy metrics, and provide the selected treatment to the patient. In a further embodiment, calculating entropy metrics includes generating multiscale entropy curves for each ROI, calculating the area under each entropy curve, assigning each ROI as positive or negative sign based on the entropy curve of each ROI, generating a similarity index for each ROI, and signing the similarity index for each ROI using the assigned sign of each ROI.

Abstract: Systems and methods for neuronavigation in accordance with embodiments of the invention are illustrated. Targeting systems and methods as described herein can generate personalized stimulation targets for the treatment of mental conditions. In many embodiments, direct stimulation of a personalized the stimulation target indirectly impacts a brain structure that is more difficult to reach via the stimulation modality. In various embodiments, the mental condition is major depressive disorder. In a number of embodiments, the mental condition is suicidal ideation.

Abstract: Provided herein are, inter alia, methods for detecting the anatomic structure of a nucleus accumbens in the brain of a subject. The method includes inserting an electrode into the ventral striatum of a subject; and detecting an oscillatory frequency of 30-40 Hz, thereby identifying the anatomic structure of a nucleus accumbens in the subject. The methods provided herein may include a step of delivering an electrical stimulation to ameliorate or prevent an OCD symptom from occurring.